Siamed'Xpress Overview

  • Founded
  • 2010
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

Siamed'Xpress General Information


Developer of proteins with serum-like glycosylation intended for research, therapeutics or diagnostics use. The company's product is designed to make it possible to humanize the clones producing therapeutic proteins in order to prolong their activity, enabling the reduction of the doses injected and side-effects.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Primary Office
  • Hôtel Technologique Morandat
  • 1480 avenue d'Arménie
  • 13120 Gardanne
  • France
+33 04 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Siamed'Xpress Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 21-May-2012 Completed Generating Revenue
To view Siamed'Xpress’s complete valuation and funding history, request access »

Siamed'Xpress Executive Team (1)

Name Title Board Seat Contact Info
Catherine Ronin-Vaisse Ph.D Founder & Chief Executive Officer
To view Siamed'Xpress’s complete executive team members history, request access »

Siamed'Xpress Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Incubateur Impulse Accelerator/Incubator Minority 000 0000 000000 0
To view Siamed'Xpress’s complete investors history, request access »